Clinical Trial Update: Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab (MK-3475) in recurrent or metastatic head and neck squamous cell carcinoma after platinum and cetuximab therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-07-06